Aptose Biosciences Inc (APS) - Total Assets
Based on the latest financial reports, Aptose Biosciences Inc (APS) holds total assets worth CA$6.34 Million CAD (≈ $4.59 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aptose Biosciences Inc - Total Assets Trend (1996–2024)
This chart illustrates how Aptose Biosciences Inc's total assets have evolved over time, based on quarterly financial data. Also see market cap of Aptose Biosciences Inc for the company's overall valuation and market capitalisation.
Aptose Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Aptose Biosciences Inc's total assets of CA$6.34 Million consist of 94.1% current assets and 5.9% non-current assets. Review APS liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 60.8% |
| Accounts Receivable | CA$0.00 | 0.0% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how Aptose Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Aptose Biosciences Inc stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aptose Biosciences Inc's current assets represent 94.1% of total assets in 2024, a decrease from 94.3% in 1996.
- Cash Position: Cash and equivalents constituted 60.8% of total assets in 2024, up from 17.0% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Aptose Biosciences Inc Competitors by Total Assets
Key competitors of Aptose Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Aptose Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.53 | 1.05 | 18.36 |
| Quick Ratio | 0.53 | 1.05 | 18.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-3.30 Million | CA$477.00K | CA$118.26 Million |
Aptose Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Aptose Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 68.22 |
| Latest Market Cap to Assets Ratio | 0.44 |
| Asset Growth Rate (YoY) | -22.0% |
| Total Assets | CA$10.13 Million |
| Market Capitalization | $4.43 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aptose Biosciences Inc's assets below their book value (0.44x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Aptose Biosciences Inc's assets decreased by 22.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Aptose Biosciences Inc (1996–2024)
The table below shows the annual total assets of Aptose Biosciences Inc from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$10.13 Million ≈ $7.33 Million |
-22.03% |
| 2023-12-31 | CA$12.99 Million ≈ $9.40 Million |
-74.54% |
| 2022-12-31 | CA$51.03 Million ≈ $36.91 Million |
-38.17% |
| 2021-12-31 | CA$82.53 Million ≈ $59.70 Million |
-34.64% |
| 2020-12-31 | CA$126.26 Million ≈ $91.34 Million |
+25.66% |
| 2019-12-31 | CA$100.48 Million ≈ $72.68 Million |
+495.59% |
| 2018-12-31 | CA$16.87 Million ≈ $12.20 Million |
+40.97% |
| 2017-12-31 | CA$11.97 Million ≈ $8.66 Million |
+38.41% |
| 2016-12-31 | CA$8.65 Million ≈ $6.25 Million |
-43.69% |
| 2015-12-31 | CA$15.35 Million ≈ $11.11 Million |
-43.73% |
| 2014-12-31 | CA$27.29 Million ≈ $19.74 Million |
+2617.29% |
| 2013-12-31 | CA$1.00 Million ≈ $726.42K |
+54.91% |
| 2012-12-31 | CA$648.24K ≈ $468.93K |
-54.70% |
| 2011-12-31 | CA$1.43 Million ≈ $1.04 Million |
-34.43% |
| 2010-12-31 | CA$2.18 Million ≈ $1.58 Million |
-68.39% |
| 2009-12-31 | CA$6.91 Million ≈ $5.00 Million |
-40.84% |
| 2008-12-31 | CA$11.67 Million ≈ $8.44 Million |
-19.32% |
| 2007-12-31 | CA$14.47 Million ≈ $10.47 Million |
+39.00% |
| 2006-12-31 | CA$10.41 Million ≈ $7.53 Million |
-52.62% |
| 2005-12-31 | CA$21.97 Million ≈ $15.89 Million |
0.00% |
| 2004-12-31 | CA$21.97 Million ≈ $15.89 Million |
-13.06% |
| 2003-12-31 | CA$25.27 Million ≈ $18.28 Million |
-18.84% |
| 2002-12-31 | CA$31.13 Million ≈ $22.52 Million |
0.00% |
| 2001-12-31 | CA$31.13 Million ≈ $22.52 Million |
-22.56% |
| 2000-12-31 | CA$40.20 Million ≈ $29.08 Million |
-16.76% |
| 1999-12-31 | CA$48.30 Million ≈ $34.94 Million |
+2125.33% |
| 1998-12-31 | CA$2.17 Million ≈ $1.57 Million |
-46.42% |
| 1997-12-31 | CA$4.05 Million ≈ $2.93 Million |
-47.34% |
| 1996-12-31 | CA$7.69 Million ≈ $5.56 Million |
-- |
About Aptose Biosciences Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloi… Read more